Holen Sie sich die Stockscreener-App
1.12
0.90%
0.01
Handel nachbörslich:
1.12
Schlusskurs vom Vortag:
$1.11
Offen:
$1.1
24-Stunden-Volumen:
364.30K
Relative Volume:
0.31
Marktkapitalisierung:
$121.18M
Einnahmen:
$4.35M
Nettoeinkommen (Verlust:
$-45.53M
KGV:
-1.037
EPS:
-1.08
Netto-Cashflow:
$-44.79M
1W Leistung:
-4.27%
1M Leistung:
-11.11%
6M Leistung:
+35.81%
1J Leistung:
+30.23%
1-Tages-Spanne:
$1.08
$1.13
1-Wochen-Bereich:
$1.07
$1.215
52-Wochen-Spanne:
$0.7201
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Firmenname
Lucid Diagnostics Inc
Sektor
Branche
Telefon
212 949 4319
Adresse
360 MADISON AVENUE, NEW YORK
Vergleichen Sie LUCD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.12 | 126.59M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Eingeleitet | BTIG Research | Buy |
| 2021-11-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Needham | Buy |
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Is Lucid Diagnostics Inc. a good long term investmentStrong return on assets - jammulinksnews.com
What drives Lucid Diagnostics Inc. stock priceSuperior return velocity - jammulinksnews.com
What analysts say about Lucid Diagnostics Inc. stockRapid growth trajectories - jammulinksnews.com
Immunovia's Strategic Hiring of Natalie Carfora: A Catalyst for Reimbursement Success and Market Expansion of PancreaSure - AInvest
Immunovia Names Natalie Carfora VP of Market Access and Reimbursement Ahead of PancreaSure Launch - AInvest
Lucid Diagnostics Inc. Stock Analysis and ForecastHigh-yield portfolio picks - jammulinksnews.com
Lucid says meeting scheduled to determine Medicare coverage for cancer test - MSN
LUCD’s 2025 Market Dance: Up 26.00% – Time to Invest? - investchronicle.com
what makes lucid diagnostics inc. stock price move sharply3x Growth Potential - Newser
Esophageal Cancer Detection Revolution: Lucid's Medicare Milestone and Its Market Impact - AInvest
Lucid says AdCom meeting set to determine cancer test coverage - Seeking Alpha
Lucid Diagnostics Inc. shares fall 5.98% intraday as MolDX convenes expert medical panel on Medicare. - AInvest
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test - Barchart.com
How Lucid Diagnostics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
What makes Lucid Diagnostics Inc. stock price move sharplyInvestor Favorite Picks - Newser
Why Lucid Diagnostics Inc. stock attracts strong analyst attentionRisk Aware High Growth Picks - Newser
Brokerages Set Lucid Diagnostics Inc. (NASDAQ:LUCD) Price Target at $3.55 - Defense World
[New] Lucid Stock Price Prediction 2024, 2025 To 2050 - Exla Resources
Lucid Diagnostics Inc.(NasdaqCM: LUCD) added to Russell Small Cap Comp Growth Index - MarketScreener
Lucid Diagnostics Inc.(NasdaqCM: LUCD) added to Russell 3000 Index - MarketScreener
Is Lucid Diagnostics, Inc. technically bullish or bearish? - MarketsMojo
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test - BioSpace
Lucid Diagnostics Holds Annual Stockholders Meeting - TipRanks
Leading California Hospital Network Launches Revolutionary 3-Minute Cancer Detection Test from Lucid Diagnostics - Stock Titan
119,887 Shares in Lucid Diagnostics Inc. (NASDAQ:LUCD) Acquired by Citadel Advisors LLC - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price - Defense World
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 By Investing.com - Investing.com South Africa
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Maintained at Buy by Ascendiant Capital | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Target Price Increased by Ascendiant | - GuruFocus
Lucid Diagnostics Files For Offering Of 36 Million Shares Of Common Stock - MarketScreener
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Lucid Diagnostics Enters $25M Sales Agreement - TipRanks
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com South Africa
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com Australia
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Indexes | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Ind - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.50 Consensus Price Target from Brokerages - Defense World
Finanzdaten der Lucid Diagnostics Inc-Aktie (LUCD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):